Medical • Artificial • Real • Time • Intelligence

MARTI helps payers and at-risk providers by identifying patients at risk of costly health events, enabling proactive intervention for prevention and mitigation.

$100 saved per member per month

DeLorean AI’s medical AI, MARTI, reduces MLR (medical loss ratio) by as much as $100PMPM and increases revenue while enhancing the quality of care and extending patients’ lives.

Identify High-Risk Members

MARTI uncovers members with undetected high-risk conditions, enabling intervention on these cases before they lead to high costs and serious health risks.

Dynamic Risk Stratification

MARTI evaluates and updates each patient’s current risk profile, ensuring that care providers receive the most up-to-date information to guide clinical decision-making.

Identify unknown patients

MARTI advises on existing members that could be high cost and pose health risks that the business doesn’t already know about.

Transition Prediction

MARTI detects and alerts healthcare providers to potential health status changes or significant medical events, fostering timely and informed care responses.

Tailored Care Recommendations

MARTI generates personalized care recommendations aimed at preventing or mitigating the impact of predicted health events, optimizing patient outcomes while managing care costs.

MARTI = Intervention & Prevention

85-87% prediction accuracy

MARTI’s predictions and forecasts have been shown to be accurate and true (95 to 99% confidence level) by three independent organizations, one of which is F5 health plan.

Real science by real scientists

4 Years of R&D – Proven, Tested. Deployed.

Led by Severence MacLauglin, Ph.D

Leading global AI scientist, former Chief of Intelligence for the Western Hemisphere at Capgemini Invent and Global Head of Artificial Intelligence for Healthcare & Life Sciences at Cognizant.


Leading to satisfied patients and higher star-ratings.

Designed for Scale


As an on-premises solution, MARTI allows clients to maintain direct control over their data, infrastructure, and security policies.

Unparalleled scope

MARTI doesn’t use sampling, instead it models the client’s whole population to capture outliers and discover sub-populations – currently over 50 million patients.

Depth of model

MARTI leverages 40-60 attributes, regardless of source, to operate. Additional data points such as lab, pharma, etc. expand its ability.


MARTI operates in AWS, Azure, Snowflake, Google’s GCP, Teradata Vantage, SambaNova RDU, and ORock cloud.


With the ability to better classify patient populations, assign risk, and predict disease state transitions, Medical AI directly leads to:

Hyper-personalized “Next Best Actions”

Gives clinical teams care pathway options to improve patient outcomes. MARTI is proven to optimize patient outcomes while reducing medical cost exposure.

Holistic Views

View populations by singular disease state or with co-morbidities.

Earlier detection and diagnosis of diseases / illnesses

Improved disease / illness management

Halted disease progressions

MARTI delivers answers proactively providing predictions and recommendations

MARTI generates real-time predictions and interventive next-best-action recommendations for care managers and medical directors to drive the most efficient treatment protocols and the best health outcomes.

Before Patients seek care

Before Claims are submitted

Before major health events occur

Before Disease states are identified

Easy to consume dashboards

MARTI’s results are delivered through easily consumable dashboards specifically tailored to the end- user needs, whether it’s mapping to a client’s existing system or using a new platform such as PowerBI or Tableau


Deferred treatment

“Sixty percent of surveyed clinicians indicated that deferred care led to an increase in complications, 30 percent reported an increase in mortality, and 55 percent noted an increase in self-medicating and forgoing necessary prescriptions.”

MARTI precisely identifies patients that are in deferred-care patterns and facing imminent events/transitions. By focusing care teams on these patients before they require intensive care, costly interventions can be avoided.

Aging Populations

“In the United States from now until the end of 2029, 10,000 people are estimated to turn 65 years old each day. Within this population the incidents of comorbidities increases significantly with more than 50% of older adults living with three or more chronic conditions (IJEPH).” – Xtelligent Healthcare Media: (September 6, 2022)

MARTI offers insurers and ACOs powerful tools to control costs as their member and patient populations age. Through precision identification of patients on the verge of transitioning to advanced and critical disease states, clinical teams can focus their resources on reducing and even preventing comorbidities.

Value Based Care

69% of employers and 61% of consumers said they prefer value-based care over fee-for-service models. – Emblem Health

Given the choice, employers and consumers both prefer value-based care systems. MARTI empowers both payers and providers to deliver on the ultimate promise of true healthcare – ensuring wellness.

Other AI services for Healthcare vs. MARTI

Other AI Services

Current AI solutions only use structured data and a portion of the available patient population to deliver broad-stroke analytics to inform users about what is going on.

the difference with MARTI

MARTI uses the entire patient population, structured and unstructured data, as well as supporting health information from personnel, EHRs, labs, etc. After performing classifications, MARTI produces predictions and next-best-action recommendations, to realize better care.

Care Modules for Chronic Illness Management

DeLorean AI currently offers four (4) modules that are ready to deploy for renal, diabetes, cardiovascular, and behavioral health. Note: our Respiratory AI is slated for release at the end of Q4 and High-risk Pregnancy in Q1 of 2024.



ESRD $15k / CKD $1200



Diabetes $2800 / Pre-Diabetes $500






Stat coming soon!



Coming in Q1 of 2024!